+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oligonucleotide API - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • PDF Icon

    Report

  • 180 Pages
  • October 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6292922
The oligonucleotide API market size was valued at USD 5.18 billion in 2025 and is estimated to grow from USD 5.59 billion in 2026 to reach USD 8.21 billion by 2031, at a CAGR of 7.98% during the forecast period (2026-2031). This report is Segmented by API Type (ASOs, Sirna, PMO, Microrna, Aptamers), Manufacturing Technology (Solid-Phase, Enzymatic, Hybrid, Others), Application (Rare/Genetic, Neurological, Cardiovascular, Oncology, Infectious, Gene Editing, Others), Status (Marketed, Clinical, Preclinical), End User (Pharma, Biotech, CRDMO and More), and Geography (N. America, Europe, and More). Forecasts are Provided in Value (USD).

Global Oligonucleotide API Market Trends and Insights

Advancing Oligonucleotide Therapeutic Pipelines

The oligonucleotide API market draws much of its near-term demand from the progression of clinical programs into later development stages. A broader set of RNA therapeutic candidates requires clinical-grade material before commercial manufacturing begins. Early-stage programs can also establish supplier relationships well before pivotal trials, which gives capable manufacturers a longer view of future demand. The 2025 approvals of fitusiran, donidalorsen, and plozasiran, following olezarsen in 2024, showed that multiple oligonucleotide approaches can reach commercial use. The approved therapies cover different treatment settings and support demand across antisense and siRNA supply chains. This progression encourages developers to secure manufacturing expertise before the timeline for large-scale supply becomes tight.

Expansion of GMP Oligonucleotide CDMO Capacity

GMP capacity is expanding as sponsors seek dependable supply for development and marketed programs in the oligonucleotide API market. Bachem inaugurated Building K in Switzerland in April 2026 after investing CHF 332.6 million (USD 407.6 million) in 2025 and planning CHF 350 million (USD 428.9 million) to CHF 400 million (USD 490.2 million) of further investment for 2026. BioSpring is building a GMP facility in Germany that covers more than 15,200 m² and is scheduled for completion in 2027. Nippon Shokubai announced a tenfold expansion of GMP-compliant nucleic acid drug API capacity in June 2025, with operations targeted for 2027. These programs broaden the number of qualified facilities that can support complex development and commercial work. They also make location, technology breadth, and regulatory experience more important in supplier selection.

High Purification, Yield, and Impurity-Control Costs

Purification remains a central constraint on the oligonucleotide API market because closely related failure sequences are difficult to remove. Solid-phase synthesis can produce molecules that differ by only 1 nucleotide, so manufacturers may need multiple ion-exchange or reverse-phase chromatography steps. Modified sequences are especially challenging because practical yields can remain below 50%. The process also creates substantial demands for buffers, testing, and documented control of each manufacturing stage. The International Society for Pharmaceutical Engineering noted that these requirements complicate scale-up and increase waste-management demands. Higher production costs can limit access when developers target larger patient populations and need lower per-dose pricing.

Other drivers and restraints analyzed in the report include:
  • Increasing Adoption of Precision Medicine and RNA-Based Therapies
  • Rising Demand for Complex Conjugated Oligonucleotide APIs
  • Specialty Phosphoramidite and Modified-Monomer Supply Bottlenecks

Segment Analysis

Antisense oligonucleotides accounted for 55.31% of the oligonucleotide API market share by API type in 2025. Their position reflects an established set of products in rare, neuromuscular, metabolic, and cardiovascular conditions. Antisense approaches remain important where intrathecal or intraocular delivery is required and systemic delivery alternatives have limited use. The installed base gives suppliers recurring experience with sequence design, process validation, and regulatory documentation. PMO APIs retain a specialized role in Duchenne muscular dystrophy exon-skipping programs. MicroRNA mimics and aptamer APIs have smaller commercial volumes but retain development potential in oncology and other therapeutic areas.

Small interfering RNA APIs are forecast to grow at 10.65% CAGR from 2026 to 2031 in the oligonucleotide API market. GalNAc conjugation supports durable gene silencing and less frequent subcutaneous dosing. Products such as Amvuttra and Leqvio show how this platform can support chronic treatment settings. These characteristics can increase annual API needs when compared with programs serving limited orphan populations. The category also raises demand for conjugation expertise and methods that preserve purity at larger scale. Suppliers that can handle both the oligonucleotide and the targeting ligand are positioned to support this shift.

Solid-phase synthesis held 68.24% of the oligonucleotide API market share by manufacturing technology in 2025. Its lead comes from long-standing process knowledge, installed GMP equipment, and regulatory precedent. The method remains widely used for established products and for many clinical programs. Its practical limits become more visible as commercial output rises because column size, solvent consumption, and waste treatment increase with scale. The International Society for Pharmaceutical Engineering reported that larger solid-phase batches can require extensive solvent handling, which complicates facilities intended for high annual volumes. These limitations are encouraging manufacturers to assess alternative methods without abandoning proven chemistry.

Hybrid chemical-enzymatic synthesis is projected to advance at 13.42% CAGR from 2026 to 2031. The approach combines chemically produced fragments with enzymatic ligation to build longer sequences. It can address the limits of single-column solid-phase production while retaining familiar phosphoramidite inputs. Fragment-based assembly may also produce impurity profiles that are more manageable than conventional shortmer failures. Liquid-phase methods are relevant for shorter modified sequences and can lower solvent use in some applications. Research on chemical ligation and liquid-phase approaches supports continued platform development for larger and more complex oligonucleotides.

Complete Report Scope:

  • By API Type
    • Antisense Oligonucleotides
    • Small Interfering RNA APIs
    • Phosphorodiamidate Morpholino Oligonucleotide APIs
    • MicroRNA Mimics and Inhibitors
    • Aptamer APIs
    • Other Emerging Types
  • By Manufacturing Technology
    • Solid-Phase Synthesis
    • Liquid-Phase Synthesis
    • Fragment Condensation
    • Enzymatic Synthesis
    • Hybrid Chemical-Enzymatic Synthesis
  • By Application
    • Rare and Genetic Diseases
    • Neurological and Neuromuscular Disorders
    • Cardiovascular and Metabolic Diseases
    • Oncology and Immuno-Oncology
    • Infectious Diseases and Antiviral Therapies
    • Gene Editing and Gene Regulation
    • Other Applications
  • By Status
    • Marketed APIs
    • Clinical-Trial APIs
    • Preclinical and Discovery-Stage APIs
  • By End User
    • Pharmaceutical Companies
    • Biotechnology Companies
    • Contract Research and Development Manufacturing Organizations
    • Academic and Research Institutes
    • Other End Users
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 41.41% of oligonucleotide API revenue in 2025. The region combines FDA regulatory experience, a dense group of RNA-focused innovators, and established GMP facilities in Massachusetts, California, and North Carolina. This combination supports both development supply and commercial manufacturing. Regulatory precedent for oligonucleotide chemistry, manufacturing, and controls documentation is a practical advantage for suppliers serving United States-bound programs. Bachem is expanding its United States capacity through 2030 as part of its broader investment program. The oligonucleotide API market in North America also benefits from proximity between developers, analytical specialists, and manufacturing partners.

Europe is the second-largest regional base, with a technical cluster across Germany, Switzerland, and the United Kingdom. Its position is supported by experienced CDMOs and by being close to European regulatory expertise. BioSpring’s German facility is intended to add substantial manufacturing capability when it is completed in 2027. Germany and Switzerland remain important production centers because of their established technical infrastructure. The United Kingdom is also strengthening strategic biomanufacturing capacity under post-Brexit industrial priorities. These factors make Europe an important alternative supply base for sponsors seeking geographic diversity in the oligonucleotide API market.

Asia-Pacific is projected to be the fastest-growing region at 10.25% CAGR from 2026 to 2031. South Korea has become a significant production hub through ST Pharm’s manufacturing activity, while Nippon Shokubai’s planned tenfold expansion adds future capacity in Japan. Cohance Lifesciences announced an INR 230 million (USD 2.39 million) investment in a cGMP oligonucleotide facility in Hyderabad in August 2025. These investments support a wider regional manufacturing network for the oligonucleotide API market. South America, the Middle East, and Africa remain early-stage regions that rely more heavily on imports. Brazil’s pharmaceutical incentives and healthcare localization efforts in the Gulf Cooperation Council could support longer-term demand.


List of Companies Covered in this Report:

  • Ajinomoto Bio-Pharma Services
  • Asymchem Inc.
  • Bachem Holding
  • BioSpring GmbH
  • CordenPharma International GmbH
  • CPC Scientific Inc.
  • Danaher Corporation and Integrated DNA Technologies
  • Genscript
  • Hongene Biotech
  • Kaneka Corporation and Eurogentec
  • LGC Biosearch Technologies
  • Lonza Group Ltd.
  • Maravai LifeSciences and TriLink BioTechnologies
  • Merck
  • Nitto Denko Avecia Inc.
  • PeptiStar Inc.
  • RiboBio Co., Ltd.
  • Sinopep Biopharma Co., Ltd.
  • ST Pharm Co., Ltd.
  • Thermo Fisher Scientific
  • Veranova
  • WuXi AppTec Co., Ltd.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Advancing Oligonucleotide Therapeutic Pipelines
4.2.2 Expansion of GMP Oligonucleotide CDMO Capacity
4.2.3 Increasing Adoption of Precision Medicine and RNA-Based Therapies
4.2.4 Rising Demand for Complex Conjugated Oligonucleotide APIs
4.2.5 Enzymatic and Hybrid Synthesis Platforms Improving Commercial Scalability
4.2.6 Regionalization of Nucleic-Acid Manufacturing Supply Chains
4.3 Market Restraints
4.3.1 High Purification, Yield, and Impurity-Control Costs
4.3.2 Specialty Phosphoramidite and Modified-Monomer Supply Bottlenecks
4.3.3 High Solvent Intensity and Environmental Compliance Burden
4.3.4 Limited Manufacturing Standardization for Long and Highly Modified Sequences
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers
4.7.2 Bargaining Power of Buyers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By API Type
5.1.1 Antisense Oligonucleotides
5.1.2 Small Interfering RNA APIs
5.1.3 Phosphorodiamidate Morpholino Oligonucleotide APIs
5.1.4 MicroRNA Mimics and Inhibitors
5.1.5 Aptamer APIs
5.1.6 Other Emerging Types
5.2 By Manufacturing Technology
5.2.1 Solid-Phase Synthesis
5.2.2 Liquid-Phase Synthesis
5.2.3 Fragment Condensation
5.2.4 Enzymatic Synthesis
5.2.5 Hybrid Chemical-Enzymatic Synthesis
5.3 By Application
5.3.1 Rare and Genetic Diseases
5.3.2 Neurological and Neuromuscular Disorders
5.3.3 Cardiovascular and Metabolic Diseases
5.3.4 Oncology and Immuno-Oncology
5.3.5 Infectious Diseases and Antiviral Therapies
5.3.6 Gene Editing and Gene Regulation
5.3.7 Other Applications
5.4 By Status
5.4.1 Marketed APIs
5.4.2 Clinical-Trial APIs
5.4.3 Preclinical and Discovery-Stage APIs
5.5 By End User
5.5.1 Pharmaceutical Companies
5.5.2 Biotechnology Companies
5.5.3 Contract Research and Development Manufacturing Organizations
5.5.4 Academic and Research Institutes
5.5.5 Other End Users
5.6 By Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East and Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East and Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
6.3.1 Ajinomoto Bio-Pharma Services
6.3.2 Asymchem Inc.
6.3.3 Bachem Holding AG
6.3.4 BioSpring GmbH
6.3.5 CordenPharma International GmbH
6.3.6 CPC Scientific Inc.
6.3.7 Danaher Corporation and Integrated DNA Technologies
6.3.8 GenScript Biotech Corporation
6.3.9 Hongene Biotech
6.3.10 Kaneka Corporation and Eurogentec
6.3.11 LGC Biosearch Technologies
6.3.12 Lonza Group Ltd.
6.3.13 Maravai LifeSciences and TriLink BioTechnologies
6.3.14 Merck KGaA
6.3.15 Nitto Denko Avecia Inc.
6.3.16 PeptiStar Inc.
6.3.17 RiboBio Co., Ltd.
6.3.18 Sinopep Biopharma Co., Ltd.
6.3.19 ST Pharm Co., Ltd.
6.3.20 Thermo Fisher Scientific Inc.
6.3.21 Veranova
6.3.22 WuXi AppTec Co., Ltd.
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Ajinomoto Bio-Pharma Services
  • Asymchem Inc.
  • Bachem Holding AG
  • BioSpring GmbH
  • CordenPharma International GmbH
  • CPC Scientific Inc.
  • Danaher Corporation and Integrated DNA Technologies
  • GenScript Biotech Corporation
  • Hongene Biotech
  • Kaneka Corporation and Eurogentec
  • LGC Biosearch Technologies
  • Lonza Group Ltd.
  • Maravai LifeSciences and TriLink BioTechnologies
  • Merck KGaA
  • Nitto Denko Avecia Inc.
  • PeptiStar Inc.
  • RiboBio Co., Ltd.
  • Sinopep Biopharma Co., Ltd.
  • ST Pharm Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • Veranova
  • WuXi AppTec Co., Ltd.